Week 2- Tempus xT 500 Publication

Question 1

How to read a publication:

Answer 1

1. ) Abstract
2. ) Introduction
3. ) Conculsions
4. ) Discussions
5. ) Results
6. ) Methods

Question 2

Abstract:

Answer 2

Summary of the major relevant sections of the publication in less than 1000 words. Used to quickly scan/review articles.

Question 3

Intro:

Answer 3

gives context to the disease state, drug, and current/historical treatment.

Question 4

Conclusion:

Answer 4

intended to help the reader understand why the research should matter to them. Summary of the main topics covered and a re-statement of the research problem.

Question 5

Discussion:

Answer 5

Interpret/ describe the significance of the findings. Strengths/limitations.

Question 6

Results section:

Answer 6

Report the findings of the study based on the methodology applied to gather information. Should state the findings of the research arranged in a logical sequence.

Question 7

Method:

Answer 7

How was the data collected and/or analyzed

Question 8

Is it important for us to know how to analyze the scientific papers?

Answer 8

Yes, we need to be able to communicate these to physicians. It will set us apart when selling Tempus. People want to see results and metrics.

Question 9

If you had 5 min to talk about an article to a doctor, what would be the main highlights you would discuss?

Answer 9

Immediately going to the abstract. Talking to the limitations and overview of the paper.

Question 10

Tempus xT publication, when was it written?

Answer 10

in 2019

Question 11

What did it analyze?

Answer 11

500 patients, 50 in each of 10 categories

Question 12

What were the categories?

Answer 12

• 8 most common cancer types
• rare malignancies
• tumors of unknown origin

Question 13

What did each patient have performed?

Answer 13

xT test

Question 14

what did the study show?

Answer 14

1. ) adding normal match to tumor analysis improves the accuracy of DNA sequencing
2. ) combining DNA sequencing and full transcriptome RNA sequencing improves therapy matching.
3. ) integration of structured clinical data improves clinical trial matching.

Question 15

T or F, addition of normal match improves accuracy?

Answer 15

True

Question 16

why does normal match improve accuracy?

Answer 16

tumor-only, you have to compare it against something. When a lab does this, they are using a “reference genome”. But with “tumor-normal” - sequencing the patients own tumor, you are comparing it against to their own DNA, the germline DNA.

Question 17

Germline variant only refers to the fact that it’s in the patient’s own DNA, T or F?

Answer 17

True, it may be germline but it doesn’t have to be one.

Question 18

Combining DNA and RNA sequencing improves therapy matching. T or F?

Answer 18

True

Question 19

Targeted therapy matching success rates:

Answer 19

29. 6% by DNA only

43. 4% by DNA+RNA (+PD-L1)

Question 20

integrated clinical data improves clinical trial matching. T or F?

Answer 20

True

Question 21

Clinical trial data:

Answer 21

Using Tempus NGS+clinical data: 96%
Tempus NGS: 77%
National Average: <20%

Question 22

What are some of the reasons:

Answer 22

1. certain clinicians will need and request to see data and evidence to feel comfortable with ordering a test.
2. ) The xT 500 publication serves as a validation study for Tempus xT and provides the data/evidence clinicians may want.
3. ) The publication demonstrates the benefits of tumor-normal match, RNA, WTS, and clinical data.
4. ) Helps me “put my money where my mouth is” with hard facts we can present evidence for.

Question 23

key takeaways

Answer 23

• The xT 500 publication demonstrates the benefits of Tempus xT.
• Normal match DNA tumor sequencing improves the accuracy of the assay results.
• Utilization of the DNA sequence plus RNA whole transcriptome sequencing improves therapy matching
• Clinical data+molecular data improves clinical trial matching overall.